Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Single-arm, open-label, single-center study to evaluate the efficacy and safety of
baricitinib for the treatment of adults with steroid-resistant/relapse immune
thrombocytopenia (ITP).